These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 9466284)

  • 1. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation.
    Woo M; Przepiorka D; Ippoliti C; Warkentin D; Khouri I; Fritsche H; Körbling M
    Bone Marrow Transplant; 1997 Dec; 20(12):1095-8. PubMed ID: 9466284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
    Kusumi E; Kami M; Kanda Y; Murashige N; Seki K; Fujiwara M; Koyama R; Komatsu T; Hori A; Tanaka Y; Yuji K; Matsumura T; Masuoka K; Wake A; Miyakoshi S; Taniguchi S
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1302-9. PubMed ID: 17162212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
    Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
    Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation.
    Jacobson P; Uberti J; Davis W; Ratanatharathorn V
    Bone Marrow Transplant; 1998 Aug; 22(3):217-25. PubMed ID: 9720734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: the effect of cyclosporine versus tacrolimus.
    Lee JT; Whitson BA; Kelly RF; D'Cunha J; Dunitz JM; Hertz MI; Shumway SJ
    J Surg Res; 2013 Sep; 184(1):599-604. PubMed ID: 23566442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible correlation of sirolimus plasma concentration with sinusoidal obstructive syndrome of the liver in patients undergoing myeloablative allogeneic hematopoietic cell transplantation.
    Kiel PJ; Vargo CA; Patel GP; Rosenbeck LL; Srivastava S
    Pharmacotherapy; 2012 May; 32(5):441-5. PubMed ID: 22499411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
    Hamazaki T; Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sasabe M; Kishimoto T; Inoue A; Kawa K
    Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.
    Kalhs P; Brugger S; Schwarzinger I; Greinix HT; Keil F; Kyrle PA; Knöbl P; Schneider B; Höcker P; Linkesch W
    Transplantation; 1995 Nov; 60(9):949-57. PubMed ID: 7491699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation.
    Yanik G; Levine JE; Ratanatharathorn V; Dunn R; Ferrara J; Hutchinson RJ
    Bone Marrow Transplant; 2000 Jul; 26(2):161-7. PubMed ID: 10918426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of two-hour intermittent intravenous infusions of tacrolimus in the allogeneic hematopoietic stem cell transplantation unit.
    Bacopoulos AJ; Ho L; Yang A; Ng P; Dara C; Loach D; Deotare U; Michelis FV; Viswabandya A; Kim DD; Lipton JH; Messner HA; Thyagu S
    J Oncol Pharm Pract; 2021 Jan; 27(1):33-39. PubMed ID: 32183586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation.
    Hiraoka A; Ohashi Y; Okamoto S; Moriyama Y; Nagao T; Kodera Y; Kanamaru A; Dohy H; Masaoka T;
    Bone Marrow Transplant; 2001 Jul; 28(2):181-5. PubMed ID: 11509936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors.
    Erer B; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Galimberti M; Giardini C; Gaziev D; Maiello A
    Bone Marrow Transplant; 1996 Jul; 18(1):157-62. PubMed ID: 8832009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study.
    Rinaldi M; Pellegrini C; Martinelli L; Goggi C; Gavazzi A; Campana C; Arbustini E; Grossi P; Regazzi M; Ippoliti G; Vigano M
    J Heart Lung Transplant; 1997 Oct; 16(10):1001-10. PubMed ID: 9361242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation.
    Wingard JR; Nash RA; Przepiorka D; Klein JL; Weisdorf DJ; Fay JW; Zhu J; Maher RM; Fitzsimmons WE; Ratanatharathorn V
    Biol Blood Marrow Transplant; 1998; 4(3):157-63. PubMed ID: 9923414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
    Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
    Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.